Expenditure has increased rapidly for the treatment of rheumatoid arthritis (RA) due to the introduction of anti-tumor necrosis factor (TNF)-alpha and anti-interleukin (IL)-1 agents (infliximab, adalimumab, etanercept and anakinra). The gene discussed is TNF; the disease is rheumatoid arthritis.